Joseph J. Larosa - 02 Nov 2026 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
04 Nov 2026, 16:04:41 UTC
Prior SEC filing
21 Aug 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Joseph LaRosa
Filing notes and source

Key filing fact

Joseph J. Larosa filed Form 4 for REGENERON PHARMACEUTICALS, INC. (REGN) on 04 Nov 2026.

Key facts

  • This page summarizes Joseph J. Larosa's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
  • 5 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 04 Nov 2026, 16:04.

Change

  • Previous filing in this sequence was filed on 21 Aug 2026.
  • Current net transaction value: -$4,311,890.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001238303 Primary reporting owner

LAROSA JOSEPH J

Relationship
EVP General Counsel and Secret
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN
Signature
/s/ Joseph LaRosa
Signature date
04 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

REGN transaction

Common Stock

Options Exercise

Transaction value
Shares
+12,283
Change %
+31%
Price
$381.92*
Shares after
52,058
Date
02 Nov 2026
Ownership
Direct
REGN transaction

Common Stock

Tax liability

Transaction value
Shares
-8,686
Change %
-17%
Price
$950.50*
Shares after
43,372
Date
02 Nov 2026
Ownership
Direct
REGN transaction

Common Stock

Sale

Transaction value
-$3,802,750
Shares
-3,939
Change %
-9.1%
Price
$965.41
Shares after
39,433
Date
02 Nov 2026
Ownership
Direct
Footnotes
F1
REGN transaction

Common Stock

Sale

Transaction value
-$509,140
Shares
-527
Change %
-1.3%
Price
$966.11
Shares after
38,906
Date
02 Nov 2026
Ownership
Direct
Footnotes
F2
REGN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
5,407
Date
02 Nov 2026
Ownership
By 2025 GRAT
REGN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
413
Date
02 Nov 2026
Ownership
By 401(k) Plan

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

REGN transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-12,283
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
12,283
Exercise price
$381.92
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents volume-weighted average price of sales of 3,939 shares of Company stock on November 2, 2026 at prices ranging from $965.00 to $965.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

Footnote F2

Represents volume-weighted average price of sales of 527 shares of Company stock on November 2, 2026 at prices ranging from $966.00 to $966.32. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

Footnote F3

The stock option award vested in four equal annual installments, commencing one year after the date of grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .